More Than a Rash: Recurrent Hepatocellular Carcinoma After Liver Transplantation
نویسندگان
چکیده
منابع مشابه
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
OBJECTIVE Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials. The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined. METHODS We retrospectively analyzed 13 patients who were treated with sorafenib for recurrent hep...
متن کاملThrombosis after liver transplantation for hepatocellular carcinoma
The influence of thrombosis on the prognosis of patients with hepatocellular carcinoma (HCC) after liver transplantation (LT) and the role of the commonest inherited thrombophilia abnormalities factor V Leiden and prothrombin G20210A in the development of thrombosis are unknown. We investigated a cohort of patients who underwent LT for HCC with the aim to estimate the incidence rate (IR) of thr...
متن کاملDe novo Hepatocellular Carcinoma after Liver Transplantation
Liver transplantation is the definitive therapy for patients with advanced liver disease and its complications. Patients who are transplanted with a diagnosis of hepatocellular carcinoma (HCC) are at risk of recurrent cancer, and these patients are monitored on a regular basis for recurrence. In contrast, de novo HCC following liver transplantation is a very rare complication, and recipients wi...
متن کاملRecurrence of hepatocellular carcinoma after liver transplantation.
Outcome after liver transplantation (OLT) clearly depends on recurrence of hepatocellular carcinoma (HCC). After recurrence, patient outcome will depend on the time and site of appearance. The aim of this study was to analyze the therapeutic implications of tumor recurrence behavior. From October 1988 to December 2005, 685 patients received OLT, including 202 due to HCC (32%). We analyzed 28 re...
متن کاملSalvage Liver Transplantation for Recurrent Hepatocellular Carcinoma within UCSF Criteria after Liver Resection
BACKGROUND Salvage liver transplantation (SLT) is restricted to patients who develop hepatocellular carcinoma (HCC) recurrence within Milan criteria (MC). Little is known about outcomes for SLT in patients with recurrent HCC within University of California San Francisco (UCSF) criteria after liver resection (LR). METHODS Between January 2001 and December 2011, 380 patients with HCC meeting UC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ACG Case Reports Journal
سال: 2019
ISSN: 2326-3253
DOI: 10.14309/crj.0000000000000107